Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5356-5364

  Gastman, Brian R ^a,b   Atarashi, Yoshinari ^a   Reichert, Torsten E ^a,c   Saito, Takao ^a   Balkir, Levent ^b   Rabinowich, Hannah ^a,b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; METALLOPROTEINASE INHIBITOR; NEUTRALIZING ANTIBODY;

APOPTOSIS; ARTICLE; CELL DEATH; CELL SURFACE; HEAD CANCER; HUMAN; HUMAN CELL; HYBRIDIZATION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; NECK CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY;

ANTIGENS, CD95; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; FAS LIGAND PROTEIN; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOBLOTTING; JURKAT CELLS; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; PHENYLALANINE; RNA, MESSENGER; THIOPHENES; TUMOR CELLS, CULTURED;

EID: 0032698214     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Whiteside, T. L. Tumor-Infiltrating Lymphocytes in Human Malignancies, R. G. Landes Co., Austin, TX, 1993.
2. Whiteside, T. L., and Rabinowich, H. The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol. Immunother., 46: 175-184, 1998.
3. Miescher, S., Stoeck, M., Qiao, L., Barras, C., Barrelet, L., and von Fliedner, V. Preferential clonogenic defect of CD8-positive T lymphocytes infiltrating human solid tumors. Cancer Res., 48: 6992-6998, 1988.
4. Rabinowich, H., Banks, M., Reichert, T., Logan, T. F., Kirkwood, J. M., and Whiteside, T. L. Expression and activity of signaling molecules in T-lymphocytes obtained from patients with metastatic melanoma before and after IL-2 therapy. Clin. Cancer Res., 2: 1263-74, 1996.
5. Reichert, T. E., Rabinowich, H., Johnson, J. T., and Whiteside, T. L. Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J. Immunother., 21: 295-306, 1998.
6. Alexander, J. P., Kudoh, S., Melsop, K. A., Hamilton, T. A., Edinger, M. G., Tubbs, R. R., Sica, D., Tuason, L., Klein, E., Bukowski, R. M., and Finke, J. T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin-2 and express interleukin-2 receptors. Cancer Res., 53: 1380-1387, 1993.
7. Rabinowich, H., Suminami, Y., Reichert, T. E., Crowley-Nowick, P., Bell, M., Edwards, R., and Whiteside, T. L. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int. J. Cancer, 68: 276-284, 1996.
8. Matsuda, M., Petersson, M., Lenke, R., Taupin, J-L., Magnusson, I., Mellstedt, H., Anderson, P., and Kiessling, R. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer, 61: 765-772, 1995.
9. Kolenko, V., Wang, Q., Riedy, M. C., O'Shea, H., Ritz, J., Cathcart, M. K., Rayman, P., Tubbs, R., Edinger, M., Novick, A., Bukowski, R., and Finke, J. Tumor-induced suppression of T lymphocytes coincides with inhibition of Jak3 expression and IL-2 receptor signaling. J. Immunol., 159: 3057-3067, 1997.
10. Rabinowich, H., Reichert, T. E., Kashii, Y., Gastman, B., Bell, M. C., and Whiteside, T. L. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TCR in tumor. J. Clin. Invest., 101: 2579-88, 1998.
11. Walker, P. R., Saas, P., and Dietrich, P-Y. Tumor expression of Fas ligand (CD 95L) and the consequences. Curr. Opin. Immunol., 10: 564-572, 1998.
12. Whiteside, T. L. Tumor-infiltrating lymphocytes in head and neck cancer. In: A. E. Chang, S. Shu (eds.), Immunotherapy of Cancer with Sensitized T Lymphocytes, pp. 133-154. R. G. Landes, Austin, TX, 1994.
13. Young, M. R. I., Wright, M. A., Lozano, Y., Mathews, J. P., Benefield, J., and Prechel, M. M. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer, 67: 333-338, 1996.
14. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counter-attack: Fas-mediated T-cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-82, 1996.
15. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bomand, T., Fontana, A., Lienard, D., Cerottini, J-C., and Tschopp, J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 4521-4524, 1996.
16. Chappell, D. B., and Restifo, N. P. T cell-tumor cell: a fatal interaction? Cancer lmmunol. Immunother., 279: 6-10, 1998.
17. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. Human lung carcinomas express Fas ligand. Cancer Res., 57: 1007-10012, 1997.
18. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., and Shanahan, F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol., 160: 5669-5675, 1998.
19. Shiraki, K., Tsuji, N., Shiroda, T., Isselbacher, K. J., and Takahashi, H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA, 94: 6420-25, 1997.
20. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J. J., and Dietrich, P. Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain. J. Clin. Invest., 99: 1173-8, 1997.
21. Mitsiades, N., Poulaki, V., Leone, A., and Tsokos, M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am. J. Pathol., 153: 1947-1956, 1998.
22. Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., and Restifo, N. P. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res., 59: 59-62, 1999.
23. Smith, D., Sieg, S., and Kaplan, D. Technical note: aberrant detection of cell surface Fas ligand and anti-peptide antibodies. J. Immunol., 160: 4159-60, 1998.
24. Stokes, T. A., Rymaszewski, M., Arscott, P. L., Wang, S. H., Bretz, J. D., Bartron, J., and Baker, J. R., Jr. Constitutive expression of FasL in thyrocytes. Science (Washington DC), 279: 1-4, 1998.
25. Fiedler, P., Schaetzlein, C. E., and Eibel, H. Constitutive expression of FasL in thyrocytes. Science (Washington DC), 279: 4-6, 1998.
26. Papoff, G., Stassi, G., DeMaria, R., Giordano, C., Galluzzo, A., Bagnasco, M., Ruberti, G., and Testi, R. Constitutive expression of FasL in thyrocytes. Science (Washington DC) 279: 6-10, 1998.
27. Heo, D. S., Snyderman, C., Gollin, S. M., Pan, S., Walker, E., Deka, R., Barnes, E. L., Johnson, J. T., and Whiteside, T. L. Biology, cytogenetics and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res., 49: 5167-5175, 1989.
28. Nagashima, S., Reichert, T. E., Kashii, Y., Suminami, Y., Chikamatsu, K., and Whiteside, T. L. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2. Cancer Gene Ther., 4: 366-376, 1997.
29. Matzinger, P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods, 145: 185-192, 1991.
30. Gavrieli, Y., Sherman, S. A., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of DNA fragmentation. J. Cell Biol., 119: 493-501, 1994.
31. Mariani, S. M., Matiba, B., Baumler, C., and Krammer, P. H. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol., 25: 2303-2307, 1995.
32. Nagata, S. Fas ligand and immune evasion: expression of a death factor by tumor cells may explain their escape from immune attack. Nat. Med., 2: 1306, 1996.
33. Daniel, P. T., and Krammer, P. H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol., 152: 5624, 1994.
34. Muraki, Y. Yoshioka, C., Tateishi, A., Fududa, J., Haneji, T., and Kobyashi, N. Localization of Fas antigen in oral squamous cell carcinoma. Br. J. Oral Maxillofacial Surg., 37: 37-40, 1999.
35. Loro, L. L., Vintermyr, O. K., Johannessen, A. C., Liavaag, P. G., and Jonsson, R. Suppression of Fas receptor and negative correlation of Fas/Ligand and with differentiation and apoptosis in oral squamous cell carcinoma. J. Oral. Pathol. Med., 28: 82-87, 1999.
36. Atarashi, Y., Kanaya, H., and Whiteside, T. L. A modified JAM assay detects apoptosis in activated lymphocytes by FasL+ human adherent tumor cells. J. Immunol. Methods, in press, 1999.
37. Strasser, A., Harris, A. W., Huang, D. C., Krammer, P. H., and Cory, S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. Proc. Natl. Acad. Sci. USA, 93: 2239-224, 1995.
38. Kiessling, R., Kono, K., Petersson, M., and Wasserman, K. Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin. Immunopathol., 18: 227-242, 1996.